Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

NCT03886649 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Insufficient Funding

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: Copanlisib
DRUG: Venetoclax

Sponsor

Swiss Cancer Institute